Occam Places Prominent Scientific Leader at High Profile Neuro Startup
In October 2024, Occam recruited Laurens Kruidenier, PhD, as CSO of Nilo Therapeutics, a New York City based biotech backed by a blue chip syndicate.
Laurens joins Nilo from Cellarity, a Flagship investment employing an algorithmic, target-agnostic approach to drug discovery, where he served as CSO.
His first CSO role came at Prometheus Biosciences, an immunology play that sold to Merck for ~$11BN in 2023. Laurens began his industrial career at GSK.
About Nilo Therapeutics
Co-founded by Charles Zuker, Ruslan Medzhitov, and Steve Liberles, Nilo Therapeutics is an NYC-based biotech founded on seminal research revealing the ability to regulate human immune response via activation of neural circuits. The company is developing a pipeline of therapeutics for autoimmune and inflammatory indications.
In late 2024, Nilo raised a $101M Series A from The Column Group, DCVC Bio and Lux Capital.
Recent Placements
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.